Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps

Immunity

Volumn 42, Issue 5, 2015, Pages 826-838

  Mitra, Suman ^a   Ring, Aaron M ^b   Amarnath, Shoba ^c   Spangler, Jamie B ^b   Li, Peng ^a   Ju, Wei ^c   Fischer, Suzanne ^b   Oh, Jangsuk ^a   Spolski, Rosanne ^a   Weiskopf, Kipp ^b   Kohrt, Holbrook ^b   Foley, Jason E ^c   Rajagopalan, Sumati ^d   Long, Eric O ^d   Fowler, Daniel H ^c   Waldmann, Thomas A ^c   Garcia, K Christopher ^b   Leonard, Warren J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; DACLIZUMAB; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; PARTIAL AGONIST; PROTEIN; PROTEIN H9 RETR; STAT5 PROTEIN; UNCLASSIFIED DRUG; INTERLEUKIN 2 RECEPTOR; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SURVIVAL TIME; T CELL LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PROTEIN ENGINEERING; PROTEIN TERTIARY STRUCTURE; SURVIVAL;

ANIMALS; CELL LINE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; HUMANS; INTERLEUKIN-2; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERLEUKIN-2; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS;

EID: 84929692931     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.04.018     Document Type: Article

References (51)

1. Beniaminovitz A., Itescu S., Lietz K., Donovan M., Burke E.M., Groff B.D., Edwards N., Mancini D.M. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N.Engl. J. Med. 2000, 342:613-619.
2. Bielekova B., Richert N., Howard T., Blevins G., Markovic-Plese S., McCartin J., Frank J.A., Würfel J., Ohayon J., Waldmann T.A., et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. USA 2004, 101:8705-8708.
3. Blaser B.W., Roychowdhury S., Kim D.J., Schwind N.R., Bhatt D., Yuan W., Kusewitt D.F., Ferketich A.K., Caligiuri M.A., Guimond M. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood 2005, 105:894-901.
4. Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012, 12:180-190.
5. Cheng G., Yu A., Malek T.R. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol. Rev. 2011, 241:63-76.
6. Chinen J., Buckley R.H. Transplantation immunology: solid organ and bone marrow. J.Allergy Clin. Immunol. 2010, 125(2):S324-S335.
7. Donohue J.H., Rosenberg S.A. The fate of interleukin-2 after invivo administration. J.Immunol. 1983, 130:2203-2208.
8. Ferrara J.L., Marion A., McIntyre J.F., Murphy G.F., Burakoff S.J. Amelioration of acute graft vs host disease due to minor histocompatibility antigens by invivo administration of anti-interleukin 2 receptor antibody. J.Immunol. 1986, 137:1874-1877.
9. Gold R., Giovannoni G., Selmaj K., Havrdova E., Montalban X., Radue E.W., Stefoski D., Robinson R., Riester K., Rana J., et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013, 381:2167-2175. SELECT study investigators.
10. Hémar A., Subtil A., Lieb M., Morelon E., Hellio R., Dautry-Varsat A. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J.Cell Biol. 1995, 129:55-64.
11. Hershberger R.E., Starling R.C., Eisen H.J., Bergh C.H., Kormos R.L., Love R.B., Van Bakel A., Gordon R.D., Popat R., Cockey L., Mamelok R.D. Daclizumab to prevent rejection after cardiac transplantation. N.Engl. J. Med. 2005, 352:2705-2713.
12. Ju W., Zhang M., Jiang J.K., Thomas C.J., Oh U., Bryant B.R., Chen J., Sato N., Tagaya Y., Morris J.C., et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of Tcells from patients with ATL and HAM/TSP. Blood 2011, 117:1938-1946.
13. Kalia V., Sarkar S., Subramaniam S., Haining W.N., Smith K.A., Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ Tcells favors terminal-effector differentiation invivo. Immunity 2010, 32:91-103.
14. Kim H.P., Imbert J., Leonard W.J. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 2006, 17:349-366.
15. Kuziel W.A., Ju G., Grdina T.A., Greene W.C. Unexpected effects of the IL-2 receptor alpha subunit on high affinity IL-2 receptor assembly and function detected with a mutant IL-2 analog. J.Immunol. 1993, 150:3357-3365.
16. Langmead B., Trapnell C., Pop M., Salzberg S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009, 10:R25.
17. Laurence A., Tato C.M., Davidson T.S., Kanno Y., Chen Z., Yao Z., Blank R.B., Meylan F., Siegel R., Hennighausen L., et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007, 26:371-381.
18. Lenardo M.J. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991, 353:858-861.
19. Levin A.M., Bates D.L., Ring A.M., Krieg C., Lin J.T., Su L., Moraga I., Raeber M.E., Bowman G.R., Novick P., et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 2012, 484:529-533.
20. Levin D., Schneider W.M., Hoffmann H.H., Yarden G., Busetto A.G., Manor O., Sharma N., Rice C.M., Schreiber G. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci. Signal. 2014, 7:ra50.
21. Liao W., Schones D.E., Oh J., Cui Y., Cui K., Roh T.Y., Zhao K., Leonard W.J. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression. Nat. Immunol. 2008, 9:1288-1296.
22. Liao W., Lin J.X., Wang L., Li P., Leonard W.J. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper Tcell lineages. Nat. Immunol. 2011, 12:551-559.
23. Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38:13-25.
24. Littman D.R., Rudensky A.Y. Th17 and regulatory Tcells in mediating and restraining inflammation. Cell 2010, 140:845-858.
25. Maeda M., Shimizu A., Ikuta K., Okamoto H., Kashihara M., Uchiyama T., Honjo T., Yodoi J. Origin of human T-lymphotrophic virus I-positive Tcell lines in adult Tcell leukemia. Analysis of Tcell receptor gene rearrangement. J.Exp. Med. 1985, 162:2169-2174.
26. Morgan D.A., Ruscetti F.W., Gallo R. Selective invitro growth of T lymphocytes from normal human bone marrows. Science 1976, 193:1007-1008.
27. Morris J.C., Janik J.E., White J.D., Fleisher T.A., Brown M., Tsudo M., Goldman C.K., Bryant B., Petrus M., Top L., et al. Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in Tcell large granular lymphocyte leukemia. Proc. Natl. Acad. Sci. USA 2006, 103:401-406.
28. Nakamura Y., Russell S.M., Mess S.A., Friedmann M., Erdos M., Francois C., Jacques Y., Adelstein S., Leonard W.J. Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature 1994, 369:330-333.
29. Nelson B.H., Lord J.D., Greenberg P.D. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature 1994, 369:333-336.
30. Noguchi M., Yi H., Rosenblatt H.M., Filipovich A.H., Adelstein S., Modi W.S., McBride O.W., Leonard W.J. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993, 73:147-157.
31. Pipkin M.E., Sacks J.A., Cruz-Guilloty F., Lichtenheld M.G., Bevan M.J., Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic Tcells. Immunity 2010, 32:79-90.
32. Reichelt P., Schwarz C., Donzeau M. Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr. Purif. 2006, 46:483-488.
33. Rickert M., Wang X., Boulanger M.J., Goriatcheva N., Garcia K.C. The structure of interleukin-2 complexed with its alpha receptor. Science 2005, 308:1477-1480.
34. Riese D.J. Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?. Expert Opin Drug Discov 2011, 6:185-193.
35. Ring A.M., Lin J.X., Feng D., Mitra S., Rickert M., Bowman G.R., Pande V.S., Li P., Moraga I., Spolski R., et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat. Immunol. 2012, 13:1187-1195.
36. Rochman Y., Spolski R., Leonard W.J. New insights into the regulation of Tcells by gamma(c) family cytokines. Nat. Rev. Immunol. 2009, 9:480-490.
37. Rosenberg S.A. IL-2: the first effective immunotherapy for human cancer. J.Immunol. 2014, 192:5451-5458.
38. Rosenberg S.A., Mulé J.J., Spiess P.J., Reichert C.M., Schwarz S.L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J.Exp. Med. 1985, 161:1169-1188.
39. Strange P.G. Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br. J. Pharmacol. 2008, 153:1353-1363.
40. Strohl W.R. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr. Opin. Biotechnol. 2009, 20:685-691.
41. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., Piccirillo C.A., Salomon B.L., Bluestone J.A. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
42. Thomas L.M., Peterson M.E., Long E.O. Cutting edge: NK cell licensing modulates adhesion to target cells. J.Immunol. 2013, 191:3981-3985.
43. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martínez-Martínez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
44. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., Neylan J., Wilkinson A., Ekberg H., Gaston R., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N.Engl. J. Med. 1998, 338:161-165. Daclizumab Triple Therapy Study Group.
45. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006, 6:595-601.
46. Waldmann T.A., Conlon K.C., Stewart D.M., Worthy T.A., Janik J.E., Fleisher T.A., Albert P.S., Figg W.D., Spencer S.D., Raffeld M., et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood 2013, 121:476-484.
47. Wang X., Rickert M., Garcia K.C. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 2005, 310:1159-1163.
48. Yodoi J., Teshigawara K., Nikaido T., Fukui K., Noma T., Honjo T., Takigawa M., Sasaki M., Minato N., Tsudo M., et al. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J.Immunol. 1985, 134:1623-1630.
49. Yu A., Zhu L., Altman N.H., Malek T.R. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009, 30:204-217.
50. *). Annu. Rev. Immunol. 2010, 28:445-489.
51. Zurawski S.M., Vega F., Doyle E.L., Huyghe B., Flaherty K., McKay D.B., Zurawski G. Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor. EMBO J. 1993, 12:5113-5119.